Zydus site clears data integrity hurdle in FDA audit?
This article was originally published in Scrip
Executive Summary
No data integrity issues appear to have emerged following a recent US FDA audit of Zydus Cadila's Moraiya site in India, though the company has yet to get an all-clear from the regulatory agency following an inspection between 28 August and 5 September last year.
You may also be interested in...
Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Precious Cargo: DHL Gears To Deliver COVID-19 Vaccines
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
WHO No-Go Not A Swan Song For Remdesivir In India?
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Need a specific report? 1000+ reports available
Buy Reports